| Dr Sara Dereath Collins, MD | |
|
16900 Science Dr Ste 200, Bowie, MD 20715-4425 | |
| (410) 573-9805 | |
| Not Available |
| Full Name | Dr Sara Dereath Collins |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 21 Years |
| Location | 16900 Science Dr Ste 200, Bowie, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023275229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD36271 (District Of Columbia) | Primary |
| Entity Name | Chesapeake Cardiac Care, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740354182 PECOS PAC ID: 4880582527 Enrollment ID: O20040305000404 |
News Archive
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.
› Verified 2 days ago
| Entity Name | Privia Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20050422000298 |
News Archive
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.
› Verified 2 days ago
| Entity Name | Precision Cardiovascular Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790137396 PECOS PAC ID: 7618263641 Enrollment ID: O20160831000492 |
News Archive
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.
› Verified 2 days ago
| Entity Name | Cupid Medical Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538753876 PECOS PAC ID: 3072913961 Enrollment ID: O20220825002791 |
News Archive
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sara Dereath Collins, MD 16900 Science Dr Ste 200, Bowie, MD 20715-4425 Ph: (410) 573-9805 | Dr Sara Dereath Collins, MD 16900 Science Dr Ste 200, Bowie, MD 20715-4425 Ph: (410) 573-9805 |
News Archive
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.
ICON plc, a global provider of drug development and commercialization solutions and services, today announced that PMG Research, Inc., part of ICON Site and Patient Recruitment, and DuPage Medical Group of Chicago, Illinois have finalized a Master Agreement formalizing a clinical research partnership.
Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.
› Verified 2 days ago
Dr. Mariam Mcconnell Bahrami, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4379 Northview Dr, Bowie, MD 20716 Phone: 301-262-2627 Fax: 301-262-8411 | |
Bai Kanu, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3233 Superior Ln, B 21, Bowie, MD 20715 Phone: 301-805-2500 Fax: 301-805-0114 | |
Sobhan A Mathew, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3048 Mitchellville Rd, Bowie, MD 20716 Phone: 301-218-1456 Fax: 301-218-1462 | |
Dr. David L Siegel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 14999 Health Center Dr, Ste 201, Bowie, MD 20716 Phone: 301-262-8188 Fax: 301-464-8233 | |
Lizy Bose Thomas, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 14999 Health Center Dr, Suite 201, Bowie, MD 20716 Phone: 301-262-8188 Fax: 301-464-8233 | |
Dr. Edwin Shadzeka, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4314 Rustling Leaves Ter, Bowie, MD 20716 Phone: 301-806-2461 |